Probiotec Ltd traded at 2.98 this Wednesday June 5th, decreasing 0.01 or 0.33 percent since the previous trading session. Looking back, over the last four weeks, Probiotec lost 5.30 percent. Over the last 12 months, its price rose by 13.74 percent. Looking ahead, we forecast Probiotec Ltd to be priced at 2.92 by the end of this quarter and at 2.74 in one year, according to Trading Economics global macro models projections and analysts expectations.
Probiotec Limited is engaged in the development, manufacturing, packing and sale of pharmaceuticals, consumer health and fast-moving consumer products in Australian and international markets. The Company owns over six manufacturing facilities in Australia and distributes its products both domestically and internationally. Its products are manufactured on behalf of a range of clients, including international companies. It also owns Multipack-LJM business, a contract packer, providing packing services for a range of pharmaceutical, consumer healthcare, cosmetics, food and beverage companies. Its subsidiaries include Probiotec Pharmaceuticals Pty Ltd, Probiotec Pharma Pty Ltd, Biotech Pharmaceuticals Australia Pty Ltd, Biotech Pharmaceuticals Pty Ltd, Probiotec (NSW) Pty Ltd, Australian Dairy Proteins Pty Ltd, Milton Pharmaceuticals Pty Ltd, Willie Labs Generics Pty Ltd, South Pack Laboratories (Aust) Pty Ltd, LJM Marketing Services Pty Ltd, Multipack-LJM Pty Ltd and LJM (NSW) Pty Ltd.